SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced the broad commercial release of two Digital Gene Expression (DGE) applications that use Illumina’s Genome Analyzer to generate genome-wide sequencing-based expression profiles of messenger and small RNA. These Digital Gene Expression applications, which have been in Early Access testing and evaluation since February 2007, offer researchers a robust platform for novel RNA discovery, accurate quantification of low-abundance messenger RNA, and measurement of gene expression in any species without the need for prior sequence knowledge.
